ECSP077315A - Proteínas de fusión de dominio de unión - Google Patents

Proteínas de fusión de dominio de unión

Info

Publication number
ECSP077315A
ECSP077315A EC2007007315A ECSP077315A ECSP077315A EC SP077315 A ECSP077315 A EC SP077315A EC 2007007315 A EC2007007315 A EC 2007007315A EC SP077315 A ECSP077315 A EC SP077315A EC SP077315 A ECSP077315 A EC SP077315A
Authority
EC
Ecuador
Prior art keywords
fusion proteins
domain fusion
union domain
union
involve
Prior art date
Application number
EC2007007315A
Other languages
English (en)
Inventor
Martha S Hayden-Ledbetter
Peter A Thompson
Jeffrey A Lebetter
Philip H Tan
Original Assignee
Turbion Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turbion Pharmaceuticals filed Critical Turbion Pharmaceuticals
Publication of ECSP077315A publication Critical patent/ECSP077315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona con construcciones y métodos para el tratamiento de enfermedades, desordenes y condiciones, que incluyen aquellas que se relacionan o que involucran desordenes auto-inmunes, inflamación, infecciones bacterianas, fungosas y virales, y enfermedades causadas o que involucran proliferación no controlada o anormal de células, incluyendo cáncer.
EC2007007315A 2004-08-11 2007-03-12 Proteínas de fusión de dominio de unión ECSP077315A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60075504P 2004-08-11 2004-08-11

Publications (1)

Publication Number Publication Date
ECSP077315A true ECSP077315A (es) 2007-04-26

Family

ID=37669267

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007315A ECSP077315A (es) 2004-08-11 2007-03-12 Proteínas de fusión de dominio de unión

Country Status (16)

Country Link
US (1) US20080181892A1 (es)
EP (1) EP1791866A2 (es)
JP (1) JP2008509666A (es)
KR (1) KR20070041781A (es)
CN (1) CN101124248A (es)
AU (1) AU2005334481A1 (es)
BR (1) BRPI0514259A (es)
CA (1) CA2578613A1 (es)
CR (1) CR8978A (es)
EC (1) ECSP077315A (es)
IL (1) IL181233A0 (es)
MX (1) MX2007001638A (es)
NO (1) NO20071302L (es)
RU (1) RU2007108538A (es)
WO (1) WO2007011363A2 (es)
ZA (1) ZA200702004B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
JP5707024B2 (ja) 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
AU2006317242A1 (en) * 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP2009529331A (ja) * 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
EP2059533B1 (en) * 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2565207A3 (en) 2007-03-14 2013-06-12 Alexion Cambridge Corporation Humaneered Anti-Factor B Antibody
US20100291023A1 (en) * 2007-05-31 2010-11-18 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP2170951A2 (en) * 2007-05-31 2010-04-07 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
CA2689695A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
CA2691819A1 (en) * 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
WO2009064838A1 (en) * 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
AR064713A1 (es) * 2007-12-28 2009-04-22 Consejo Nac Invest Cient Tec Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
PT2132228E (pt) * 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
US8518410B2 (en) * 2009-03-10 2013-08-27 Baylor Research Institute Fusion protein with HIV antigen
US8193321B2 (en) * 2008-09-03 2012-06-05 Genentech, Inc. Multispecific antibodies
JP5651474B2 (ja) * 2008-10-09 2015-01-14 オリエンタル酵母工業株式会社 β−アミロイド前駆体蛋白質由来マトリックスメタロプロテアーゼ−２インヒビターペプチドと組織メタロプロテアーゼ阻害物質との融合タンパク質
CN101402674B (zh) * 2008-10-20 2011-07-27 中国人民解放军第三军医大学 附睾蛋白酶抑制剂的功能肽段及应用
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
KR20240007725A (ko) 2009-11-02 2024-01-16 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료학적 뉴클레아제 조성물 및 방법
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
AU2012249360B2 (en) 2011-04-29 2015-12-24 University Of Washington Therapeutic nuclease compositions and methods
KR20140049993A (ko) 2011-06-02 2014-04-28 메사추세츠 인스티튜트 오브 테크놀로지 메타핵 줄기 세포의 dsRNA/DNA 하이브리드 게놈 복제 중간체
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying fusion proteins containing serphin
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
WO2013025598A1 (en) * 2011-08-12 2013-02-21 The Children's Hospital Of Philadelphia Degranulation indicator and methods of use thereof
SI2804878T1 (sl) 2012-01-20 2018-12-31 Genzyme Corporation Protitelesa proti-CXCR3
KR101536151B1 (ko) * 2012-01-31 2015-07-14 서울대학교산학협력단 새로운 ＣＴＬＡ-４ＩｇＧ 융합 단백질
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US10132816B2 (en) 2013-03-14 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Measurement of FGF21 as a biomarker of fructose metabolism
JP6583794B2 (ja) 2013-05-20 2019-10-02 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 多発性骨髄腫のためのｇｅｐ５モデル
JP6422977B2 (ja) 2013-08-30 2018-11-14 エイプリルバイオ カンパニー リミテッド 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法
ES2759252T3 (es) 2013-10-31 2020-05-08 Resolve Therapeutics Llc Fusiones y métodos terapéuticos de nucleasa-albúmina
ES2700149T3 (es) 2014-02-24 2019-02-14 Takeda Gmbh Proteínas de fusión de UTI
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2016168758A1 (en) * 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
CN105483104B (zh) * 2016-01-05 2021-01-15 北京志道生物科技有限公司 牛胰蛋白酶的生产工艺
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN115702242A (zh) * 2020-04-20 2023-02-14 医药控股公司 一种改性的细菌透明质酸酶多肽、生产方法、药物组合物及其用途
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US6291662B1 (en) * 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5851983A (en) * 1987-12-28 1998-12-22 Teijin Limited Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
WO1993013207A2 (en) * 1991-12-31 1993-07-08 Zymogenetics, Inc. Novel human transglutaminases
EP0668875A4 (en) * 1992-10-12 1999-05-26 Agen Ltd ANTI-COAGULAR AGENT ON BLOOD CLOTH, METHOD FOR PRODUCING THE SAME AND ITS USE.
US5428014A (en) * 1993-08-13 1995-06-27 Zymogenetics, Inc. Transglutaminase cross-linkable polypeptides and methods relating thereto
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US6072041A (en) * 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2433877C (en) * 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas

Also Published As

Publication number Publication date
US20080181892A1 (en) 2008-07-31
MX2007001638A (es) 2009-02-12
JP2008509666A (ja) 2008-04-03
WO2007011363A2 (en) 2007-01-25
IL181233A0 (en) 2008-04-13
KR20070041781A (ko) 2007-04-19
CN101124248A (zh) 2008-02-13
EP1791866A2 (en) 2007-06-06
NO20071302L (no) 2007-05-07
WO2007011363A3 (en) 2007-07-05
ZA200702004B (en) 2008-11-26
AU2005334481A1 (en) 2007-01-25
CR8978A (es) 2008-10-03
CA2578613A1 (en) 2007-01-25
BRPI0514259A (pt) 2008-06-03
RU2007108538A (ru) 2008-09-20

Similar Documents

Publication Publication Date Title
ECSP077315A (es) Proteínas de fusión de dominio de unión
NL301145I2 (nl) Tirbanibulin
CL2020000483A1 (es) Nuevos usos de derivados de piperidinil–indol.
AU2018338314A1 (en) Protein degraders and uses thereof
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
CR20140422A (es) Composiciones de enzima digestiva estable
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
EP3799871A3 (en) Pyrazol-3-ones that activate pro-apototic bax
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
CL2011002300A1 (es) Compuestos derivados de 2,4-diamiropirimidinas 5-sustitudas inhibidoras de quinasa ptk2; preparaciones farmaceuticas; y su uso para el tratamiento y/o la prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes.
WO2010034015A3 (en) Modulating the alternative complement pathway
EA201300871A1 (ru) ПРОИЗВОДНЫЕ (1,2,4)ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2019009610A (es) Metodos para aumentar en plasma sanguineo la 2'-desoxiuridina (durd) y la inhibicion de la timidilato sintasa.
MX2021013602A (es) Inhibidores de jak.
CR20210029A (es) MÉTODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA